Results 271 to 280 of about 63,982 (290)
Some of the next articles are maybe not open access.
Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy
The American Journal of the Medical Sciences, 1988Adoptive immunotherapy, the administration of interleukin-2 (IL-2) and interleukin-2 activated cells, leads to tumor regression in some patients with advanced cancer. Although this new therapeutic modality offers hope for the future, at present, a multitude of toxicities limit the total dose and duration of therapy.
Alpha A. Fowler+5 more
openaire +2 more sources
Adoptive Immunotherapy of Ovarian Carcinoma
Gynecologic Oncology, 2002SCOPUS: le.j ; info:eu-repo/semantics ...
de Gramont, Aimery+5 more
openaire +2 more sources
NK cell adoptive immunotherapy
Blood, 2005Comment on Miller et al, page [3051][1] In this issue of Blood, Miller and colleagues present data on the administration of haploidentical NK cells to cancer patients. They identify a feasible and safe method for in vivo NK cell expansion and clinical efficacy.
openaire +4 more sources
An artificial solution for adoptive immunotherapy
Trends in Biotechnology, 2003Abstract Adoptive immunotherapy is a promising strategy in the battle against cancer and infectious diseases and the recently developed artificial antigen-presenting cell (aAPC) overcomes several obstacles for this therapy. The aAPC recapitulates the natural in vivo antigen-presenting cell (APC)–T cell interactions by coupling human leukocyte ...
openaire +3 more sources
Adoptive T‐cell transfer in cancer immunotherapy
Immunology & Cell Biology, 2006Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred
Tey, Siok-Keen+2 more
openaire +4 more sources
Adoptive T cell immunotherapy for cytomegalovirus
Expert Opinion on Biological Therapy, 2009Cytomegalovirus (CMV) is a major opportunistic pathogen following allogeneic transplantation, reflecting the inability of depressed host immunity to contain viral replication. Current antiviral drugs are limited by toxicities and lack of efficacy in established CMV disease, making adoptive immunotherapeutic strategies aimed at hastening virus-specific ...
openaire +3 more sources
CASE FOR ADOPTIVE IMMUNOTHERAPY IN CANCER
The Lancet, 1982Patients with normal immune systems may be unable to mount effective defences against solid tumours because of (1) the generation of suppressor T cells in the low zone tolerance response elicited by the low concentrations of antigen furnished by slow growing solid tumours; (2) the ineffectiveness of the cytolytic T-cell response when the tumour cell ...
openaire +3 more sources